



Express Mail No. EL852691935US

PTO/SB/088 (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/640,041
		Filing Date	August 15, 2000
		First Named Inventor	W. Michael Kavanaugh
		Art Unit	1644
		Examiner Name	Michail A. Belyavsky
Sheet 1	of 1	Attorney Docket Number	59516-135 / PP-01615.002

RECEIVED JUN 1 2003 TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
MB		PINKAS-KRAMARSKI ET AL., <i>Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions</i> , EMBO Jour., 1995, 15:2452-2457	
MB		SHELLY ET AL., <i>Epregrulin is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes</i> , J. Biol Chem., 1998, pp. 10496-10505, 273:17	
MB		SEPP-LORENZINO, L. ET AL., <i>Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells</i> , Oncogene, 1996, 12:1679-1687	

Examiner Signature		Date Considered	02/11/04
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered; whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to